ESH MM 2018 | Opinion: value of MRD as an endpoint in hem-onc clinical trials

Robert Hills

Measurable residual disease (MRD) is a hot topic, with it’s full potential still to be fully realized. We spoke to Robert Hills from the University of Oxford, Oxford, UK, about his thoughts on the value of MRD as an endpoint in clinical trials in the hemato-oncology field. This interview took place at the European School of Haematology (ESH) International Conference on MM 2018, held in Mandelieu, France.

Share this video